Adipokines and risk of rheumatoid arthritis: a Mendelian randomization study

Jiahao Zhu  
Hangzhou Medical College

Haiyan Zheng  
Newcastle University

Yasong Li  
Zhejiang Provincial People's Hospital

Tianle Wang  
Zhejiang province people's hospital

Yaohong Zhong  
Hangzhou medical college

Chunhong Fan  
Hangzhou medical college

Yingjun Li (mailto:yingjunguqing2006@126.com)  
Hangzhou Medical College

Research article

Keywords: Adipokines, Causality, Genetic epidemiology, Mendelian randomization, Rheumatoid arthritis

DOI: https://doi.org/10.21203/rs.3.rs-36474/v1

License: Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Background:** Circulating adipokines levels have been reported to be associated with the risk of rheumatoid arthritis (RA). However, it is still unclear whether these associations are causal or biased by reverse causation or residual confounding. This study aimed to assess potential causal roles of five adipokines (namely, adiponectin, leptin, resistin, chemerin, and retinol-blinding protein 4 [RBP4]) in the occurrence of RA.

**Methods:** We conducted a two-sample Mendelian randomization analysis to investigate these associations. We used summary-level data from genome-wide association studies (GWASs) for adipokines in individuals of European ancestry as the exposure, and a separate large-scale meta-analysis of a GWAS which included 14,361 RA cases and 43,923 controls of European ancestry as the outcome. Genetic variants were selected as instrumental variables if robustly genome-wide significant in their associations with adipokines. The causal effects were estimated using the inverse-variance weighted method in the primary analysis. Sensitivity analyses were performed to warrant that bias due to genetic pleiotropy was unlikely.

**Results:** The circulating resistin was found to be the only adipokinet factor having statistical significance, with higher levels causally associated with the risk of RA (odds ratio: 1.28; 95% confidence interval: [1.07, 1.53] per unit increase in the natural log-transformed resistin). In contrast, associations of adiponectin, leptin, chemerin, and RBP4 with risk of RA were not statistically significant. The MR assumptions did not seem to be violated. Sensitivity analyses yielded consistent findings.

**Conclusions:** Genetically predicted circulating resistin levels were positively associated with RA risk. Our analysis suggested that resistin may play a notable causal role in RA pathogenesis. It would be beneficial for the development of clinical as well as public health strategies that target appropriate levels of resistin for future RA intervention.

Introduction

Rheumatoid arthritis (RA) is a chronic multisystem disease marked by symmetrical inflammatory polyarthritis, which usually spreads from small joints to larger joints [1]. It accounted for 3.5 million disability-adjusted life-years globally according to a recent report on the Global Burden of Diseases [2]. Although the definitive causes of RA remain unknown, the reams of evidence point to the immune-mediated etiology related with chronic inflammation and articular destruction [3].

Adipokines are a class of multifunctional molecules secreted by adipose tissue, which could effectively regulate inflammation via autocrine/paracrine and endocrine pathways [4]. Since adipokines have the potential to modulate target tissues and cells in bone, synovium, cartilage and various immune cells [5], they may play an important role in RA pathogenesis. To date, a large number of case-control studies have been undertaken to explore the association between circulating adipokines and risk of RA, but inconsistent results were reported. Some studies showed that RA patients had higher circulating levels of
adipokines compared with healthy controls [6–8], while some others found either no association or a significant association in the opposite direction [9–11]. The conflicting findings may be attributed to the small study sample sizes, clinical heterogeneity, or the use of different adipokines measurements for assessment. Besides, the association established in those observational studies cannot be equated to a causal relationship without further evidence, as bias due to reverse causation and/or residual confounding may occur.

Free of the limitations of traditional observational studies, Mendelian randomization (MR) is a novel method that uses genetic variants as instrumental variables (IVs) or ‘proxies’ for exposures of interest to test the potential causal effect of a modifiable risk factor on the outcome [12–14]. In particular, two-sample MR has been widely considered in situations when measuring the exposure and outcome in the same set of individuals is infeasible [15]. The present research applies the two-sample MR approach to investigate whether there exists a genuine association between circulating adipokines and risk of RA. Following the Mendel's second law that alleles are independently isolated and randomly assigned from parents to offspring during gamete formation, MR can avoid the influence of potential confounding factors [14]. Moreover, it overcomes the problem of reverse causation, as genotype is basically fixed since conception and consequently precedes the diseases process [14].

In this paper, we assess the causal associations between several genetically predicted adipokines and RA risk using the two-sample MR approach along with sensitivity analyses. Based on the genetic IVs from several published genome-wide association studies (GWASs), potential causal effects of key adipokines, namely, adiponectin, leptin, resistin, chemerin, and retinol-binding protein 4 (RBP4), on the risk of developing RA are examined.

**Materials And Methods**

**Data sources**

We downloaded genetic data for five adipokines (adiponectin, leptin, resistin, chemerin and RBP4) as well as RA from the IEU GWAS database (https://gwas.mrcieu.ac.uk), which provide a large collection of GWAS summary statistics. Specifically, the genetic data for circulating adiponectin levels were obtained from a meta-analysis of GWASs in 39,883 individuals of European ancestry [16], and the genetic data for circulating leptin levels adjusted for body mass index (BMI) from 23 population based GWAS with 32,161 individuals of European ancestry [17]. The published meta-analysis of GWASs identified several loci associated with circulating chemerin levels in 2,791 individuals of European descent from 3 independent studies [18]. The genetic data for resistin and RBP4 were acquired from a recent GWAS in 3,301 individuals of European descent [19]. Our investigation is carried out based on publicly available data; therefore, no additional ethical approval would be required.

We extracted the RA information from a separate large-scale meta-analysis of trans-ethnic GWAS, including a total of >100,000 participants of European and Asian ancestries [20]. In this instance,
performing a two-sample MR analysis would be suitable to estimate the causal effects [15]. To mitigate the risk of bias induced by population stratification, only summary-level data from 58,284 subjects of European ancestry (14,361 RA cases and 43,923 controls) were used in the present analysis. The following genetic information was collected, including the rs ID for single nucleotide polymorphisms (SNPs), beta coefficient with corresponding standard error, effect allele, non-effect allele, effect allele frequency, name of the phenotype, physical position of SNPs (chromosome and position), sample size, association $p$-value, and units in which the effects are presented. All RA cases had been diagnosed by a board-certified rheumatologist or met the 1987 diagnosis criteria of the American College of Rheumatology for RA [21]. Details of the study protocols of above the mentioned GWASs are available from the previous publications [16–20].

**Selection Of Instrumental Variables**

We chose SNPs that are robustly associated with adipokines at the genome-wide significance level ($P < 5 \times 10^{-8}$). To ensure the selected SNPs being mutually independent, we estimated the linkage disequilibrium (LD) between the SNPs using European samples from the 1000 Genome Project as the reference panel. A smaller association $p$-value indicates a stronger adipokine-SNP association; we selected the SNPs that reached the LD threshold ($r^2 > 0.001$) with relatively small association $p$-values. For any specifically requested SNPs that were not found in the RA GWAS, we used SNPs in strong LD ($r^2 > 0.8$) to substitute the requested SNPs. We further eliminated SNPs that lacked necessary information and/or linked with intermediate allele frequencies.

**Statistical analysis**

Validity of the causal estimates obtained from the MR approach relies on three key assumptions of an IV: 1) The genetic variants were strongly associated with circulating adipokine levels; 2) The genetic variants were not related to potential confounding factors of the adipokine-RA association; 3) The genetic variants must only affect the risk of RA through the adipokines rather than any other pathway (no potential pleiotropic effects) [22]. These assumptions apply for all the analyses below. Figure 1 is an illustrative diagram showing how these assumptions are accommodated in the present study.

Two-sample MR analysis was performed to estimate the causal effects, as the summary statistics for exposure and outcome had been extracted from different GWASs. We calculated $R^2$ and the $F$ statistics to estimate the proportion of variance in adipokines explained by the IV (each selected SNP) and to assess the strength of instruments. In the main analysis, we calculated the causal effect estimates obtained from different SNPs based on the Wald ratio method [23], applying the fixed-effects inverse-variance weighted (IVW) method, with each selected genetic variant satisfying the three assumptions of an IV [24]. Including multiple variants in an MR analysis may introduce pleiotropic genetic variants that are invalid IVs [23]. Sensitivity analyses were then performed to ensure that potential pleiotropy on the MR causal estimates is unlikely. In particular, weighted-median (WM) method can relax the assumptions of MR: even
if nearly half of the genetic variants were invalid instruments, the WM method can still provide a robust and consistent estimate of the causal effect [22]. Additionally, MR-Egger regression analysis was used to account for the presence of directional pleiotropy according to its intercept term ($P < 0.05$); the slope of this regression also helped examine the consistency of a causal estimate, while taking into account the pleiotropic effects [25]. Of note, the MR-Egger regression analysis has the limitation of generating estimates with low precision, and may be influenced by outlying genetic variants [25]. We used the MR pleiotropy residual sum and outlier (MR-PRESSO) method to further test the presence of pleiotropy. Causal estimates in our analysis were thus obtained after outlier correction [26]. Cochran Q test was employed to assess the statistical heterogeneity between SNPs in IVW estimates, with $P < 0.05$ considered as significantly heterogeneous. We also implemented the random-effects IVW method [27, 28] to account for possible heterogeneity between IV estimates. To investigate the reliability of the causal association, we performed the “leave-one-out” analysis: each SNP was excluded in turn to explore the potential impact of individual SNP on the summary causal estimates.

To eliminate the effects of known confounding factors on causality, we extracted relevant phenotypes of the selected SNPs in GWAS catalog (https://www.ebi.ac.uk/gwas). These MR analyses were repeated after excluding SNPs associated with secondary phenotype at the genome-wide significance threshold ($P < 5 \times 10^{-8}$). Since SNPs near the ADIPOQ locus were closely related to the coding of circulating adiponectin [29], we restricted SNPs in ADIPOQ gene to further evaluate the causal association between adiponectin and risk of RA.

All statistical analyses were conducted using RStudio version 3.6.3 with “TwoSampleMR” R packages. Two-sided $P$ values were computed, with $P < 0.05$ considered as statistically significant.

**Results**

We identified 10 independent SNPs associated with adiponectin, 4 associated with leptin, 3 associated with resistin, 1 associated with chemerin, and 1 associated with RBP4 as IVs. Supplementary Table 1 summarises the information of the SNPs used as the IVs. All selected SNPs were strongly associated with adipokines and, by contrast, not associated with RA. The $F$ statistics for all SNPs > 10, suggesting that the analysis is unlikely to be affected by weak instrument bias.

As presented in Table 1, resistin was found as the only adipokinetiic factor positively associated with the risk of RA. The casual odds ratio (OR) was $1.28$ (95% confidence interval (CI): $1.07, 1.53; P = 0.007$) per unit increase in natural log-transformed resistin levels using the IVW method, and $1.25$ (95% CI: $1.02, 1.54; P = 0.031$) using the WM method. This causal association became statistically insignificant along with a wider 95% CI in the MR-Egger regression analysis, which may be attributed to inadequate statistical power. Furthermore, the intercept of the MR-Egger regression model did not suggest a horizontal pleiotropy effect across the gentic variants ($P = 0.833$). Cochran's Q test did not indicate heterogeneity between Wald ratio estimates based on individual SNPs. Due to the limited number of SNPs for resistin, we were unable to conduct a MR-PRESSO test to further detect the presence of pleiotropy. There was little
evidence of causal associations between adiponectin, leptin, chemerin as well as RBP4 with risk of RA. Scatter plots, forest plots and funnel plots for adiponectin, leptin as well as resistin are presented in Supplementary Fig. 1–3. We note that the causal estimates of individuals SNP for chemerin and RBP4 were reported in Table 2, and thus would not be repeated duplicately in plots. Since only one SNP associated with chemerin and RBP4 each, we were unable to perform leave-one-out analysis and Cochran's Q test. For these reasons, the supplementary figures visualise analysis results for three adipokines only.
| Exposure | MR method | Number of SNPs | OR  | 95% CI     | Association p-value | Cochran’s Q Statistic | Heterogeneity p-value | MR Egger intercept (p-value) a |
|----------|-----------|----------------|-----|------------|---------------------|-----------------------|-----------------------|-------------------------------|
| Adiponectin | IVW       | 10             | 1.20| 0.93, 1.56 | 0.164               | 10.15                 | 0.338                 |                               |
|          | WM        | 10             | 1.26| 0.90, 1.76 | 0.185               |                       |                       |                               |
|          | MR Egger  | 10             | 1.21| 0.77, 1.90 | 0.436               |                       |                       |                               |
|          | MR PRESS O b | 10        | 1.24| 0.98, 1.57 | 0.107               |                       |                       |                               |
| Leptin   | IVW       | 4              | 1.88| 0.80, 4.44 | 0.148               | 0.56                  | 0.905                 |                               |
|          | WM        | 4              | 1.59| 0.60, 4.20 | 0.353               |                       |                       |                               |
|          | MR Egger  | 4              | 0.41| 3.02e-09, 5.65e+07 | 0.935               |                       |                       | 0.036 (0.888)               |
|          | MR PRESS O b | 4        | 1.25| 0.73, 2.13 | 0.462               |                       |                       |                               |
| Resistin | IVW       | 3              | 1.28| 1.07, 1.53 | 0.007               | 0.15                  | 0.926                 |                               |
|          | WM        | 3              | 1.25| 1.02, 1.54 | 0.031               |                       |                       |                               |
|          | MR Egger  | 3              | 1.39| 0.74, 2.60 | 0.493               |                       |                       | -0.015 (0.833)              |
| Chemerin | Wald ratio | 1             | 1.58| 0.81, 3.07 | 0.180               |                       |                       |                               |
| RBP4     | Wald ratio | 1             | 1.13| 0.78, 1.64 | 0.530               |                       |                       |                               |
In the leave-one-out analysis, not a single SNP was found to substantially drive the overall risk estimates of adipokines on the risk of RA (Supplementary Fig. 4). After searching the secondary phenotypes of the SNPs used as IVs in the GWAS catalog, we found that several SNPs were also associated with obesity-related traits, including triglyceride, cholesterol levels, waist-hip ratio and body fat percentage with genome-wide significance (Supplementary Table 2). Similar results were obtained after excluding the pleiotropic SNPs potentially related to obesity. In sensitivity analyses where we restrict SNPs in ADIPOQ gene to further evaluate the causal role of adiponectin on RA, similar null association was found.

**Discussion**

In this paper, we explored the genetic association between adipokines and the development of RA, finding that per one unit increase in natural log-transformed resistin levels could be causally associated with 28% increased risk of RA occurrence. Whereas, little evidence supported causal associations of genetically predicted adiponectin, leptin, chemerin or RBP4 levels with the RA risk. Our analysis results indicate that regulating the circulating resistin to appropriate levels may lower the incidence of RA, which could be useful in future clinical practice. To the best of our knowledge, this is the first MR study to evaluate the potential causal association between circulating adipokine levels and risk of RA.

A large number of observational epidemiological studies have been undertaken to investigate the role of adipokines in the occurrence and progression of RA. Two recent meta-analyses of case-control studies demonstrated that circulating adiponectin levels could be significantly higher in the RA patients than those in the health controls [30, 31]. However, it was also reported separately that adiponectin levels were not related to RA activity [30, 32]. Meanwhile, the findings from meta-analyses consistently indicated that patients with RA may have higher circulating leptin levels compared with the control group [33–35]. Two of these studies further established a correlation between leptin levels and RA activity [34, 35]. Several case-control studies have also suggested associations of chemerin and RBP4 concentrations with RA [36, 37]. However, our MR results suggested that genetically predicted levels of adiponectin, leptin, chemerin or RBP4 were not causally associated with risk of RA. The inconsistency between our MR analysis and the previous observational studies may be attributed to the following reasons. Firstly, the previously published results are mostly based on retrospective case-control studies with a small sample size, which
are particularly prone to recall and selection biases. This thereby leads to an even weaker causal argument. Secondly, residual confounding (e.g., the adipokines may be correlated with other factors that impact on RA risk) and reverse causation (e.g., RA may have resulted in high or low circulating adipokine levels) may further limit the ability of causal inference in the traditional observational studies. Thirdly, MR studies provide causal estimates of the impact of lifetime adipokine levels on RA, which might diverge from the short-term effects as assessed in traditional observational studies.

For resistin, our MR results were broadly compatible with the findings of the previous meta-analysis outcomes [38]. Several biological mechanisms have been proposed to interpret the potential effect of resistin on the pathogenesis of RA. It is widely recognized that RA is a persistent inflammatory disease, which is related to several inflammatory cytokines [39]. Šenolt et al. reported that resistin was expressed in different inflammatory cells of RA synovial tissue, including macrophages (CD68), B lymphocytes (CD20) and plasma cells (CD138) [40]. Those authors speculated that resistin was involved in the activation of these cells as a signaling molecule in RA. Subsequently, a case-control study found a positive association of serum resistin with C-reactive protein levels in RA patients, further supporting the potential pro-inflammatory effects of resistin in this disease. Furthermore, synovial liquid resistin levels have been claimed to be significantly associated with rheumatoid factor and anti-citrullinated protein antibody [41], both of which are markers of RA. Cellular analysis suggested that resistin down-regulates the expression of microRNA 206 via protein kinase C delta (PKC-δ/AMPK) signaling pathway to promote endothelial progenitor cell (EPC) migration and RA angiogenesis. In addition, resistin induced the vascular endothelial growth factor (VEGF) expression, which was also associated with EPC migration and tube formation [42]. Therefore, resistin plays an important role in the pathogenesis of RA and may being a potential target for RA intervention.

Our investigation has some potential limitations. Firstly, it is known that genetic variants only explain a relatively small proportion of variation in adipokines, which may lead to inadequate power to detect causal associations in studies with small sample sizes [43]. Secondly, pleiotropy is considered to be the most challenging limitation of MR analysis. Even though none of the performed MR analyses showed an indication of pleiotropy, we were unable to completely rule out the possibility that pleiotropy had affected the results. Thirdly, our MR analysis were conducted using participants of European ancestry. While restricting the investigation to racially homogeneous populations reduces the population stratification bias, our findings may not be applicable to other populations for different genetic backgrounds. Finally, for the use of summary-level data, we were unable to perform subgroup analyses to address study-specific factors, e.g., age, sex and other RA risk factors.

In conclusion, the present MR study indicates that genetically predicted circulating resistin levels are positively associated with risk of RA. This can be beneficial for the development of clinical as well as public health strategies. Nevertheless, we encourage further prospective studies and MR analyses with more genetic instruments and longitudinal studies, which follow up RA patients over time monitoring the risk factors and outcome, to be conducted to confirm the results.
Abbreviations

BMI: Body mass index; EPC: Endothelial progenitor cell; GWAS: Genome-wide association study; IV: Instrumental variable; IVW: Inverse-variance weighted; LD: Linkage disequilibrium; MR: Mendelian randomization; MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier; RA: Rheumatoid arthritis; RBP4: Retinol-blinding protein 4; SNP: Single nucleotide polymorphisms; WM: Weighted-median

Declarations

Ethics approval and consent to participate

Participating studies of the GWAS meta-analyses have received prior approval by relevant institutional review boards, and informed consent was obtained from each study participant. The current study was carried out based on publicly available data; therefore, no additional ethical approval would be required.

Consent for publication

Not applicable.

Availability of data and materials

RA summary statistics analysed during the current study are available at https://gwas.mrcieu.ac.uk.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by National Natural Science Foundation of China [grant number 81703289].

Authors' contributions

All authors interpreted the data, critically revised the manuscript for important intellectual content, approved the final version of the manuscript, and agreed to be responsible for all aspects of the work.

Acknowledgements

The authors thank all the participants and researchers for their participation in the current study.

References

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
2. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–71.

3. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis Immunity. 2017;46(2):183–96.

4. IJ MD, Liu SC, Huang CC, Kuo SJ, Tsai CH, Tang CH. Associations between Adipokines in Arthritic Disease and Implications for Obesity. Int J Mol Sci. 2019;20(6).

5. Azamar-Llamas D, Hernandez-Molina G, Ramos-Avalos B, Furuza-Carballeda J. Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2017;2017:5468023.

6. Olama SM, Senna MK, Elarman M. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol Int. 2012;32(3):683–90.

7. Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol. 2009;36(4):724–30.

8. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol. 2011;38(2):229–35.

9. Hizmetli S, Kisa M, Gokalp N, Bakici MZ. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis ? Rheumatol Int. 2007;27(4):335–8.

10. Li P, Yang L, Ma CL, Liu B, Zhang X, Ding R, Bi LQ. Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms. Clin Rheumatol. 2015;34(6):1025–30.

11. Forsblad d’Elia H, Pullerits R, Carlsten H, Bokarewa M. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology. 2008;47(7):1082–7.

12. Burgess S, Daniel RM, Butterworth AS, Thompson SG, Consortium EP-I. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol. 2015;44(2):484–95.

13. Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.

14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–63.

15. Lawlor DA. Commentary. Two-sample Mendelian randomization: opportunities and challenges. Int J Epidemiol. 2016;45(3):908–15.

16. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, Henneman P, Heid IM, Kizer JR, Lyytikainen LP, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and
metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012;8(3):e1002607.

17. Kilpelainen TO, Carli JF, Skowronska AA, Sun Q, Kriebel J, Feitosa MF, Hedman AK, Drong AW, Hayes JE, Zhao J, et al. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nat Commun. 2016;7:10494.

18. Tonjes A, Scholz M, Breitfeld J, Marzi C, Grallert H, Gross A, Ladenvall C, Schleinitz D, Krause K, Kirsten H, et al. Genome wide meta-analysis highlights the role of genetic variation in RARRES2 in the regulation of circulating serum chemerin. PLoS Genet. 2014;10(12):e1004854.

19. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–9.

20. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–81.

21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.

22. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304–14.

23. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717–26.

24. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.

25. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.

26. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.

27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

28. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783–802.

29. Borges MC, Lawlor DA, de Oliveira C, White J, Horta BL, Barros AJ. Role of Adiponectin in Coronary Heart Disease Risk: A Mendelian Randomization Study. Circ Res. 2016;119(3):491–9.

30. Lee YH, Bae SC. Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Int J Rheum Dis. 2018;21(3):664–72.
31. Zhang MY, Dini AA, Yang XK, Li LJ, Wu GC, Leng RX, Pan HF, Ye DQ. Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis. Arch Dermatol Res. 2017;309(8):625–35.

32. Ogaji DS, Giles S, Daker-White G, Bower P. Development and validation of the patient evaluation scale (PES) for primary health care in Nigeria. Prim Health Care Res Dev. 2017;18(2):161–82.

33. Tian G, Liang JN, Pan HF, Zhou D. Increased leptin levels in patients with rheumatoid arthritis: a meta-analysis. Ir J Med Sci. 2014;183(4):659–66.

34. Cao H, Lin J, Chen W, Xu G, Sun C. Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: A meta-analysis and systematic review. Autoimmunity. 2016;49(8):547–53.

35. Lee YH, Bae SC. Circulating leptin level in rheumatoid arthritis and its correlation with disease activity: a meta-analysis. Z Rheumatol. 2016;75(10):1021–7.

36. Zhao L, Yamaguchi Y, Ge X, Robinson WH, Morser J, Leung LLK. Chemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients. Arthritis Res Ther. 2018;20(1):132.

37. Wei Y, Xia N, Zhang W, Huang J, Ren Z, Zhu L, Zhang Z, Yang L. Serum retinol-binding protein 4 is associated with insulin resistance in patients with early and untreated rheumatoid arthritis. Joint Bone Spine. 2019;86(3):335–41.

38. Huang Q, Tao SS, Zhang YJ, Zhang C, Li LJ, Zhao W, Zhao MQ, Li P, Pan HF, Mao C, et al. Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Clin Rheumatol. 2015;34(10):1713–20.

39. Fatel ECS, Rosa FT, Simao ANC, Dichi I. Adipokines in rheumatoid arthritis. Adv Rheumatol. 2018;58(1):25.

40. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, Anderlova K, Muller-Ladner U, Pavelka K, Haluzik M. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis. 2007;66(4):458–63.

41. Fadda SM, Gamal SM, Elsaid NY, Mohy AM. Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression. Z Rheumatol. 2013;72(6):594–600.

42. Nagaev I, Andersen M, Olesen MK, Nagaeva O, Wikberg J, Mincheva-Nilsson L, Andersen GN. Resistin Gene Expression is Downregulated in CD4(+) T Helper Lymphocytes and CD14(+) Monocytes in Rheumatoid Arthritis Responding to TNF-alpha Inhibition. Scand J Immunol. 2016;84(4):229–36.

43. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell JS, Kivimaki M, Brunner EJ, Whittaker JC, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol. 2016;45(5):1600–16.

44. Legend.
**Supplementary Table S1** Summary information on the SNPs used as genetic instruments for the five adipokines.

**Supplementary Table 2** Potential secondary phenotypes of the genetic variants used for adipokines (from the GWAS catalog).

**Supplementary Fig. 1** Scatter plots of causal associations between adipokines and risk of RA. The slope of each line represents the causal association using the corresponding MR analysis model.

**Supplementary Fig. 2** Forest plots of individual and summary estimates for causal associations between adipokines and RA risk.

**Supplementary Fig. 3** Funnel plots to detect heterogeneity, which show no evidence of asymmetry. Directional horizontal pleiotropy is suggested to be null.

**Supplementary Fig. 4** Leave-one-out plot to assess if a single SNP drives association between adipokines with RA risk.

### Figures

![Diagram of causal associations between adipokines and RA](image)

**Figure 1**

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigureS4.tif](SupplementaryFigureS4.tif)
- [SupplementaryFigureS3.tif](SupplementaryFigureS3.tif)
• SupplementaryFigureS2.tif
• SupplementaryFigureS1.tif
• SupplementaryTable2.docx
• SupplementaryTable1.docx